Leo Lens Pharma Announces Corporate Name Change to MediPrint Ophthalmics

Leo Lens Pharma has announced a corporate name change to MediPrint Ophthalmics, effective immediately. The company also announced it has successfully closed an over-subscribed Seed round fundraising.

The company’s rebranding to MediPrint Ophthalmics is based on input from stakeholders and prospective customers and is intended to align its name with the proprietary pipeline of products it is developing. Now is an ideal time for this change as MediPrint Ophthalmics prepares to enter the clinic where its lead asset, a proprietary drug-eluting, comfort-enhancing contact lens to treat patients suffering from primary open-angle glaucoma or ocular hypertension, will be tested in human trials for the first time, according to a company news release. Its new name is the beginning of a refreshed identity which will span from its web site to its logo to all other notable corporate identifiers.

Another milestone for the company is the close of an over-subscribed Seed round fundraising. The total raised in the Seed round exceeded $4.0 million, with $2.6 million from new investors, including from the lead investor which is the venture arm of a leading global ophthalmic pharmaceutical company. As previously reported, these funds are intended primarily to support the phase 2a clinical study along with the end of phase 2 meeting with the FDA.

“This is an especially exciting time for MediPrint Ophthalmics as we start a new stage in our journey to help protect sight for patients suffering from potentially debilitating eye diseases such as glaucoma,” Dan Myers, CEO of MediPrint Ophthalmics, said in the news release. “Our new corporate identity will make it easier for patients and eye care professionals to identify us and understand what we aim to do. And closing our Seed round successfully is a tribute to the hard work our team has done to date and to the vision for the future of eye care we gratefully share with a group of passionate investors,” he added.